Aims-To study the amplification of the Cyclin DI gene (CCND1) in human breast carcinoma; to relate this to Cyclin DI protein expression; to relate these parameters to recognised pathological prognostic factors, including oestrogen receptor (ER) status.
There is a continual search for new prognostic markers in human breast cancer which may refine the selection of patients for particular treatment regimes.
Cyclins are proteins which are involved in the control of the cell cycle.' One such protein, Cyclin Dl1, has a role in the control of the transition between G1 and S phase in the cell cycle.2 High expression of Cyclin D1 is observed during G1 followed by low expression during S phase. 34 Deregulated expression of Cyclin D 1 causes abnormalities in growth control, resulting in a decrease in the duration of G1 . 56 The gene encoding Cyclin D 1, termed CCND1, D11S287 or PRADI, is located on band qI 3 of chromosome 117, and has potential as an oncogene.8"' Accumulating evidence suggests that CCND1 is the bcl-l gene." 12 Autoradiographs were produced by exposure to a piece ofpre-flashed Hyperfilm-TM (Amersham, Little Chalfont, UK) for two to seven days at 80°C. The optical density readings of each probe binding to lymphocyte DNA from patient blood was measured. From this, an average ratio of CCND 1 and c-myc to IgJH chain probe was calculated. The normal range was defined as the average ratio + 2SD. Values above this range were regarded as representive of gene amplification.
IMMUNOCYTOCHEMISTRY
Representative sections selected from each tumour were mounted on APES (2% 3'-aminopropyltriethoxysilane) coated slides and high pressure antigen retrieval was used. 36 A monoclonal antibody directed against Cyclin D1 (a gift from Dr Jiri Bartek, Danish Cancer Society) was used at a dilution of 1 in 2000 in phosphate buffered saline at pH 7-4 overnight.33 A commercially available monoclonal antibody directed against human oestrogen receptor (Dako-ERlD5; Dako, High Wycombe, UK) was used at a dilution of 1 in 100 in Tris buffered saline at pH 7-2 for one hour. The indirect avidin-biotin immunoperoxidase technique was used to demonstrate antibody binding sites. Negative (primary antibody excluded) and positive controls (test slides supplied with antibody) were included with each batch of slides stained.
All cases were assessed independently by two pathologists and any difference of opinion on initial evaluation was resolved by subsequent discussion. In this study neither CCND 1 amplification nor protein expression seemed to be related to known histological prognostic markers. This may be because of the small number of tumour samples studied. There was, however, a weak association between Cyclin D1 expression and high ER expression. This supports the hypothesis that over expression of Cyclin D 1 may define a subgroup of ER positive tumours that have an unexpectedly poor prognosis. 23 In the future the classification of tumours on the basis of their pattern of genetic alterations may add to currently established markers and enable refinement of existing classifications. This would have an immediate impact on patient care and may also lead to the use of treatments whose design is based on the biological consequences of gene mutations. An important step towards this goal is the development of a fuller understanding of how genetic alterations and the expression of gene products relate to the development ofthe malignant phenotype.
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